DENVER, Colo. (247marketnews.com) -- Autonomix Medical (NASDAQ:AMIX) is giving investors a fresh reason to watch the stock closely: the medical-device developer is bringing in another $4.9 million in gross proceeds through the immediate exercise of existing warrants, this time at $5.75 per share, while issuing a new package of warrants exercisable at $6.25.
The deal is more than a financing footnote. It lands just days after Autonomix reported a potentially important regulatory milestone: completion of a Good Laboratory Practice preclinical study supporting a future FDA submission. The company said final histology and laboratory analyses supported the study's safety and performance objectives.
The latest financing calls for an investor to exercise warrants covering 857,462 shares, generating approximately $4.9 million before fees and expenses. In exchange, Autonomix will issue 535,913 Series E-1 warrants and 535,913 Series E-2 warrants, each exercisable at $6.25 and expiring five years after issuance. The transaction is expected to close around August 26, subject to customary conditions.
That creates an intriguing push-and-pull for shareholders: fresh capital for a company racing toward clinical and regulatory milestones, but a substantial new pool of warrants that could ultimately translate into additional shares.
The financing follows a similar July transaction in which Autonomix generated approximately $2.6 million from the exercise of existing warrants and issued new warrants with a $5.75 exercise price. The company's July 28 SEC filing reported approximately $5.1 million in cash and 971,043 shares outstanding at that time.
Meanwhile, the technology story is getting broader. On August 4, Autonomix announced a new U.S. patent covering technology designed to “sense, map and selectively target nerves” associated with tumors, cancer-related pain, organ function and other autonomic nervous-system disorders.
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.